146 related articles for article (PubMed ID: 9949292)
1. Detection and clinical correlations of ras gene mutations in human ovarian tumors.
Varras MN; Sourvinos G; Diakomanolis E; Koumantakis E; Flouris GA; Lekka-Katsouli J; Michalas S; Spandidos DA
Oncology; 1999; 56(2):89-96. PubMed ID: 9949292
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
3. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
[TBL] [Abstract][Full Text] [Related]
4. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
5. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
[TBL] [Abstract][Full Text] [Related]
6. Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids.
Dokianakis DN; Varras MN; Papaefthimiou M; Apostolopoulou J; Simiakaki H; Diakomanolis E; Spandidos DA
Clin Exp Metastasis; 1999 Jun; 17(4):293-7. PubMed ID: 10545015
[TBL] [Abstract][Full Text] [Related]
7. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
[TBL] [Abstract][Full Text] [Related]
8. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
9. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
[TBL] [Abstract][Full Text] [Related]
10. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
[TBL] [Abstract][Full Text] [Related]
11. K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.
Høgdall EV; Høgdall CK; Blaakaer J; Christensen L; Bock JE; Vuust J; Glud E; Kjaer SK;
Gynecol Oncol; 2003 Apr; 89(1):31-6. PubMed ID: 12694651
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
[TBL] [Abstract][Full Text] [Related]
13. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
14. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
[TBL] [Abstract][Full Text] [Related]
15. [K-ras mutation analysis in ovarian serous borderline and malignant tumors].
Ma L; Guo LN; Liang ZY; Ren XY; Wu SF
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253
[TBL] [Abstract][Full Text] [Related]
16. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.
Morita K; Ono Y; Fukui H; Tomita S; Ueda Y; Terano A; Fujimori T
Pathol Int; 2000 Mar; 50(3):219-23. PubMed ID: 10792785
[TBL] [Abstract][Full Text] [Related]
17. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
18. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
19. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.
Malisic E; Jankovic R; Jakovljevic K; Radulovic S
J BUON; 2011; 16(4):701-7. PubMed ID: 22331725
[TBL] [Abstract][Full Text] [Related]
20. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
